patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_296734 | REC_0006801 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.3 | 56 | female | 0 | 15 | 5.8 | 5 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:35:58.522288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274814 | REC_0006802 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 8.4 | 72 | female | 1 | 8 | 5.3 | 2 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:35:58.522520+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_933727 | REC_0006803 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 10.5 | 64 | female | 0 | 20 | 5 | 4 | alectinib 600 mg BID | 17.4 | true | MSS | 2026-03-15T05:35:58.522755+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862114 | REC_0006804 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 11.6 | 64 | female | 1 | 19 | 5.3 | 2 | alectinib 600 mg BID | 22 | false | MSS | 2026-03-15T05:35:58.522988+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_263824 | REC_0006805 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 34 | 11.9 | 61 | female | 0 | 8 | 5.1 | 6 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:58.523224+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_409523 | REC_0006806 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 8.4 | 82 | female | 2 | 12 | 5.2 | 1 | osimertinib 80 mg daily | 31.7 | false | MSS | 2026-03-15T05:35:58.523450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839140 | REC_0006807 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 6.9 | 70 | male | 0 | 14 | 6.3 | 1 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:35:58.523686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319083 | REC_0006808 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 16.8 | 60 | male | 0 | 0 | 3.9 | 1 | osimertinib 80 mg daily | 24.1 | true | MSS | 2026-03-15T05:35:58.523921+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978258 | REC_0006809 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16 | 60 | male | 1 | 8 | 5.4 | 3 | sotorasib 960 mg daily | 16.9 | true | MSI-H | 2026-03-15T05:35:58.524187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952935 | REC_0006810 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 14.8 | 78 | male | 2 | 7 | 5.1 | 7 | sotorasib 960 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:35:58.524427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_662260 | REC_0006811 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 11 | 60 | female | 0 | 13 | 6.8 | 2 | alectinib 600 mg BID | 19.1 | true | MSS | 2026-03-15T05:35:58.524665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_140948 | REC_0006812 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.4 | 80 | female | 1 | 11 | 2 | 2 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:35:58.524896+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_468378 | REC_0006813 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 17.2 | 65 | female | 0 | 20 | 5.4 | 8 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:58.525187+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832074 | REC_0006814 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 11.2 | 70 | male | 2 | 8 | 5.9 | 8 | sotorasib 960 mg daily | 6.7 | true | MSS | 2026-03-15T05:35:58.525427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_576125 | REC_0006815 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 13.8 | 48 | female | 0 | 11 | 5 | 1 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:58.525667+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_335588 | REC_0006816 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 6 | 77 | female | 0 | 8 | 6.7 | 3 | entrectinib 600 mg daily | 6.2 | true | MSS | 2026-03-15T05:35:58.525897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142564 | REC_0006817 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.7 | 70 | male | 1 | 12 | 4.7 | 5 | pembrolizumab 200 mg q3w | 14.5 | true | MSS | 2026-03-15T05:35:58.526127+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644208 | REC_0006818 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 8.8 | 69 | male | 1 | 17 | 3.6 | 6 | alectinib 600 mg BID | 17.5 | false | MSS | 2026-03-15T05:35:58.526357+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149978 | REC_0006819 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 10.8 | 67 | male | 1 | 13 | 5.5 | 7 | osimertinib 80 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.526594+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480559 | REC_0006820 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 6.2 | 71 | female | 3 | 8 | 5.9 | 1 | alectinib 600 mg BID | 23.4 | true | MSS | 2026-03-15T05:35:58.526825+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399698 | REC_0006821 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 7.8 | 57 | male | 0 | 10 | 5.1 | 6 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.527061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_587472 | REC_0006822 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 12.4 | 73 | female | 2 | 23 | 4 | 6 | osimertinib 80 mg daily | 12.8 | false | MSS | 2026-03-15T05:35:58.527298+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_727958 | REC_0006823 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 3.3 | 67 | female | 1 | 15 | 5.6 | 6 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.527526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_935078 | REC_0006824 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 12.7 | 66 | female | 1 | 22 | 5 | 1 | sotorasib 960 mg daily | 11.8 | true | MSI-H | 2026-03-15T05:35:58.527762+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469561 | REC_0006825 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 9.7 | 83 | male | 2 | 21 | 6.4 | 4 | entrectinib 600 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:58.527993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340685 | REC_0006826 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 9.6 | 76 | female | 2 | 34 | 4.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 6 | true | MSS | 2026-03-15T05:35:58.528301+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760064 | REC_0006827 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 9 | 67 | female | 1 | 6 | 4.1 | 1 | osimertinib 80 mg daily | 23.6 | true | MSS | 2026-03-15T05:35:58.528535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_541159 | REC_0006828 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 4 | 73 | female | 1 | 59 | 5.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.4 | false | MSS | 2026-03-15T05:35:58.528763+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267566 | REC_0006829 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 13.9 | 68 | female | 1 | 13 | 5.2 | 2 | osimertinib 80 mg daily | 15.7 | false | MSI-H | 2026-03-15T05:35:58.529000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939319 | REC_0006830 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 14.5 | 76 | female | 1 | 7 | 5.1 | 4 | alectinib 600 mg BID | 7.8 | false | MSS | 2026-03-15T05:35:58.529231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865364 | REC_0006831 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.5 | 66 | female | 1 | 4 | 4.9 | 5 | osimertinib 80 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:58.529466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880155 | REC_0006832 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 10.3 | 71 | female | 1 | 5 | 5.7 | 1 | osimertinib 80 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:35:58.529696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_941747 | REC_0006833 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 26 | 6 | 69 | female | 0 | 17 | 5.9 | 6 | pembrolizumab 200 mg q3w | 14.4 | true | MSS | 2026-03-15T05:35:58.529925+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_395747 | REC_0006834 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.6 | 66 | female | 0 | 22 | 6.4 | 1 | alectinib 600 mg BID | 21.1 | false | MSS | 2026-03-15T05:35:58.530160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813986 | REC_0006835 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 16.2 | 73 | female | 1 | 23 | 4.1 | 7 | osimertinib 80 mg daily | 10.7 | false | MSI-H | 2026-03-15T05:35:58.530395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_710295 | REC_0006836 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 17 | 8.8 | 54 | male | 0 | 7 | 6 | 1 | osimertinib 80 mg daily | 25.6 | false | MSS | 2026-03-15T05:35:58.530623+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_628603 | REC_0006837 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 14.6 | 73 | male | 1 | 15 | 4.3 | 3 | osimertinib 80 mg daily | 11.5 | true | MSI-H | 2026-03-15T05:35:58.530859+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173797 | REC_0006838 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.6 | 69 | female | 1 | 19 | 6.3 | 5 | entrectinib 600 mg daily | 4.7 | false | MSS | 2026-03-15T05:35:58.531090+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970926 | REC_0006839 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 7.7 | 57 | female | 0 | 9 | 4.9 | 1 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:35:58.531371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_663565 | REC_0006840 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 18.2 | 61 | male | 0 | 20 | 5.4 | 7 | osimertinib 80 mg daily | 7.5 | true | MSS | 2026-03-15T05:35:58.531608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197236 | REC_0006841 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 6.6 | 76 | male | 1 | 20 | 5.4 | 8 | osimertinib 80 mg daily | 12.2 | true | MSS | 2026-03-15T05:35:58.531842+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819496 | REC_0006842 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.1 | 62 | female | 1 | 7 | 6.1 | 5 | entrectinib 600 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:58.532128+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480640 | REC_0006843 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 12.5 | 77 | male | 1 | 25 | 6.1 | 2 | osimertinib 80 mg daily | 9.6 | false | MSS | 2026-03-15T05:35:58.532374+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183808 | REC_0006844 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8.9 | 61 | female | 0 | 19 | 6.7 | 5 | alectinib 600 mg BID | 8.4 | false | MSS | 2026-03-15T05:35:58.532608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_667446 | REC_0006845 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 12.6 | 69 | female | 1 | 22 | 5.2 | 5 | alectinib 600 mg BID | 7.4 | false | MSI-H | 2026-03-15T05:35:58.532854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511629 | REC_0006846 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 12.6 | 67 | female | 1 | 14 | 6.5 | 5 | entrectinib 600 mg daily | 10.9 | true | MSI-H | 2026-03-15T05:35:58.533089+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764013 | REC_0006847 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 9.3 | 47 | male | 0 | 17 | 6.3 | 1 | entrectinib 600 mg daily | 13.6 | true | MSS | 2026-03-15T05:35:58.533325+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455162 | REC_0006848 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 22 | 13.3 | 64 | male | 1 | 11 | 5.5 | 1 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:58.533561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244362 | REC_0006849 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 32 | 10.6 | 44 | female | 0 | 13 | 5.6 | 1 | osimertinib 80 mg daily | 16.1 | false | MSI-H | 2026-03-15T05:35:58.533796+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_704614 | REC_0006850 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 14.3 | 72 | male | 2 | 24 | 2.6 | 5 | osimertinib 80 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:35:58.534033+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194835 | REC_0006851 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 6.4 | 65 | female | 0 | 11 | 6 | 1 | entrectinib 600 mg daily | 6.8 | true | MSS | 2026-03-15T05:35:58.534267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994679 | REC_0006852 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14.5 | 69 | female | 0 | 19 | 6.1 | 9 | osimertinib 80 mg daily | 14.2 | false | MSS | 2026-03-15T05:35:58.534552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730269 | REC_0006853 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 19 | 18.2 | 67 | female | 0 | 9 | 5.5 | 1 | osimertinib 80 mg daily | 22.2 | true | MSS | 2026-03-15T05:35:58.534789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101318 | REC_0006854 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 4.5 | 61 | male | 1 | 24 | 5.5 | 2 | osimertinib 80 mg daily | 25.1 | true | MSS | 2026-03-15T05:35:58.535022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600942 | REC_0006855 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 15.4 | 64 | male | 1 | 18 | 4.5 | 8 | pembrolizumab 200 mg q3w | 9.3 | false | MSS | 2026-03-15T05:35:58.535262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_741925 | REC_0006856 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 18 | 78 | female | 2 | 7 | 5.5 | 7 | osimertinib 80 mg daily | 7.2 | false | MSI-H | 2026-03-15T05:35:58.535499+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726260 | REC_0006857 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 7.5 | 77 | male | 2 | 13 | 5 | 1 | osimertinib 80 mg daily | 17.2 | true | MSS | 2026-03-15T05:35:58.535729+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571533 | REC_0006858 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 25 | 8.2 | 66 | female | 0 | 46 | 2.4 | 0 | carboplatin + paclitaxel + pembrolizumab | 22.7 | true | MSS | 2026-03-15T05:35:58.535957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646684 | REC_0006859 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 33 | 8.6 | 64 | female | 0 | 10 | 5.2 | 2 | osimertinib 80 mg daily | 7.7 | true | MSS | 2026-03-15T05:35:58.536225+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246915 | REC_0006860 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5 | 57 | male | 0 | 48 | 7.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.8 | true | MSS | 2026-03-15T05:35:58.536462+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_746823 | REC_0006861 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 6.5 | 73 | female | 1 | 21 | 7 | 6 | pembrolizumab 200 mg q3w | 12.2 | false | MSS | 2026-03-15T05:35:58.536692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_593885 | REC_0006862 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 6.8 | 88 | female | 1 | 24 | 4.5 | 1 | sotorasib 960 mg daily | 8 | true | MSS | 2026-03-15T05:35:58.536928+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138733 | REC_0006863 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 24 | 5 | 80 | female | 3 | 7 | 5.8 | 0 | osimertinib 80 mg daily | 19.4 | true | MSS | 2026-03-15T05:35:58.537160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668998 | REC_0006864 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 8.5 | 70 | female | 2 | 19 | 4.8 | 6 | entrectinib 600 mg daily | 15 | false | MSS | 2026-03-15T05:35:58.537393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712543 | REC_0006865 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 4.3 | 59 | male | 1 | 33 | 4.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:35:58.537695+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_813181 | REC_0006866 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 14 | 71 | female | 1 | 5 | 6.7 | 5 | osimertinib 80 mg daily | 12.4 | false | MSS | 2026-03-15T05:35:58.537932+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755475 | REC_0006867 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 12.1 | 65 | male | 0 | 7 | 4.9 | 7 | osimertinib 80 mg daily | 14.6 | false | MSS | 2026-03-15T05:35:58.538171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565621 | REC_0006868 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 3.6 | 60 | female | 1 | 32 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.9 | false | MSS | 2026-03-15T05:35:58.538404+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544694 | REC_0006869 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 7.4 | 74 | female | 2 | 20 | 5.3 | 6 | sotorasib 960 mg daily | 10.6 | false | MSS | 2026-03-15T05:35:58.538639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345433 | REC_0006870 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10.7 | 62 | female | 1 | 17 | 6.5 | 4 | alectinib 600 mg BID | 13 | false | MSS | 2026-03-15T05:35:58.538874+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255493 | REC_0006871 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 7.9 | 62 | male | 0 | 17 | 5.7 | 1 | osimertinib 80 mg daily | 16.5 | false | MSS | 2026-03-15T05:35:58.539106+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849066 | REC_0006872 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 27 | 6.1 | 68 | female | 0 | 55 | 6.2 | 2 | pembrolizumab 200 mg q3w | 25 | true | MSS | 2026-03-15T05:35:58.539338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124840 | REC_0006873 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.8 | 68 | male | 1 | 68 | 7.5 | 7 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:35:58.539570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211254 | REC_0006874 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 6.3 | 71 | female | 1 | 17 | 5.3 | 1 | sotorasib 960 mg daily | 15 | true | MSS | 2026-03-15T05:35:58.539798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865949 | REC_0006875 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 11.5 | 53 | female | 0 | 16 | 8.2 | 1 | osimertinib 80 mg daily | 30.8 | true | MSS | 2026-03-15T05:35:58.540032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_475913 | REC_0006876 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.1 | 67 | female | 1 | 54 | 7.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 28.3 | false | MSS | 2026-03-15T05:35:58.540290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510212 | REC_0006877 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 16.1 | 77 | female | 2 | 9 | 5.2 | 2 | sotorasib 960 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:58.540526+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546479 | REC_0006878 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.4 | 73 | female | 2 | 13 | 6.1 | 6 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:58.540810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_949093 | REC_0006879 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 14.3 | 58 | female | 1 | 13 | 4.6 | 2 | osimertinib 80 mg daily | 23.8 | false | MSS | 2026-03-15T05:35:58.541054+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527174 | REC_0006880 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 8.6 | 68 | female | 1 | 6 | 6.4 | 5 | pembrolizumab 200 mg q3w | 13.1 | false | MSS | 2026-03-15T05:35:58.541282+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402504 | REC_0006881 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6 | 69 | female | 1 | 77 | 7.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.8 | true | MSS | 2026-03-15T05:35:58.541512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344320 | REC_0006882 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 17 | 59 | male | 1 | 13 | 3.8 | 8 | osimertinib 80 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:58.541747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887270 | REC_0006883 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 29 | 7.1 | 64 | male | 1 | 35 | 5.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 24.5 | false | MSS | 2026-03-15T05:35:58.541980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_241139 | REC_0006884 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 5.6 | 59 | male | 1 | 29 | 6.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 19.3 | true | MSS | 2026-03-15T05:35:58.542210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_145257 | REC_0006885 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 9.8 | 53 | female | 0 | 42 | 4.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:35:58.542444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737723 | REC_0006886 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 34 | 10.7 | 71 | female | 1 | 13 | 6.6 | 1 | osimertinib 80 mg daily | 22.5 | false | MSS | 2026-03-15T05:35:58.542674+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149363 | REC_0006887 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.3 | 82 | female | 1 | 16 | 7.3 | 7 | osimertinib 80 mg daily | 13.2 | false | MSS | 2026-03-15T05:35:58.542904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445440 | REC_0006888 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11 | 60 | male | 1 | 11 | 4 | 5 | osimertinib 80 mg daily | 13.7 | true | MSI-H | 2026-03-15T05:35:58.543136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309489 | REC_0006889 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 15.8 | 77 | female | 2 | 18 | 4.2 | 6 | osimertinib 80 mg daily | 14.4 | true | MSS | 2026-03-15T05:35:58.543368+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510930 | REC_0006890 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 19 | 8.8 | 62 | female | 0 | 15 | 4.5 | 0 | entrectinib 600 mg daily | 21.6 | false | MSS | 2026-03-15T05:35:58.543601+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_876759 | REC_0006891 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 12.4 | 60 | male | 0 | 15 | 7.1 | 1 | osimertinib 80 mg daily | 22.1 | false | MSS | 2026-03-15T05:35:58.543889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560579 | REC_0006892 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 24 | 11.5 | 58 | male | 1 | 1 | 6.7 | 2 | alectinib 600 mg BID | 15.6 | false | MSS | 2026-03-15T05:35:58.544189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419067 | REC_0006893 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 13.7 | 74 | female | 1 | 21 | 4.8 | 3 | alectinib 600 mg BID | 8.3 | true | MSS | 2026-03-15T05:35:58.544431+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688320 | REC_0006894 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 13.2 | 70 | female | 3 | 16 | 5.5 | 2 | sotorasib 960 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:58.544679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_195805 | REC_0006895 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 16.2 | 62 | female | 0 | 15 | 6.8 | 2 | sotorasib 960 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:58.544918+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_737708 | REC_0006896 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 11.1 | 62 | male | 1 | 5 | 5.5 | 2 | pembrolizumab 200 mg q3w | 17.8 | false | MSI-H | 2026-03-15T05:35:58.545155+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766701 | REC_0006897 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.4 | 81 | female | 2 | 52 | 6.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 16.5 | true | MSS | 2026-03-15T05:35:58.545382+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262030 | REC_0006898 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 7.4 | 72 | female | 1 | 67 | 4.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.6 | false | MSS | 2026-03-15T05:35:58.545613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_441590 | REC_0006899 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 15 | 10.8 | 66 | female | 1 | 19 | 5.6 | 1 | entrectinib 600 mg daily | 21.4 | false | MSI-H | 2026-03-15T05:35:58.545845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144466 | REC_0006900 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 12.1 | 70 | female | 1 | 20 | 6.7 | 8 | osimertinib 80 mg daily | 11.1 | false | MSI-H | 2026-03-15T05:35:58.546083+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.